Swartz GM - Search Results

1

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM. LaVallee TM, et al. Among authors: swartz gm. Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107. Mol Cancer Ther. 2008. PMID: 18566218

2

Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.

Shah JH, Agoston GE, Suwandi L, Hunsucker K, Pribluda V, Zhan XH, Swartz GM, LaVallee TM, Treston AM. Shah JH, et al. Among authors: swartz gm. Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. doi: 10.1016/j.bmc.2009.08.038. Epub 2009 Aug 21. Bioorg Med Chem. 2009. PMID: 19762246

3

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS. LaVallee TM, et al. Cancer Res. 2003 Jan 15;63(2):468-75. Cancer Res. 2003. PMID: 12543804

4

Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis.

Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, Green SJ. Shah JH, et al. Among authors: swartz gm. J Med Chem. 1999 Aug 12;42(16):3014-7. doi: 10.1021/jm990083y. J Med Chem. 1999. PMID: 10447943 No abstract available.

5

2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.

Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. Pribluda VS, et al. Among authors: swartz gm. Cancer Metastasis Rev. 2000;19(1-2):173-9. doi: 10.1023/a:1026543018478. Cancer Metastasis Rev. 2000. PMID: 11191057 Review.

6

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. Mabjeesh NJ, et al. Among authors: swartz gm. Cancer Cell. 2003 Apr;3(4):363-75. doi: 10.1016/s1535-6108(03)00077-1. Cancer Cell. 2003. PMID: 12726862 Free article.

7

Antibodies to phospholipids and liposomes: binding of antibodies to cells.

Fogler WE, Swartz GM Jr, Alving CR. Fogler WE, et al. Among authors: swartz gm jr. Biochim Biophys Acta. 1987 Oct 2;903(2):265-72. doi: 10.1016/0005-2736(87)90215-x. Biochim Biophys Acta. 1987. PMID: 2820489

8

Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.

Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Hembrough TA, et al. Among authors: swartz gm. Blood. 2004 May 1;103(9):3374-80. doi: 10.1182/blood-2003-07-2234. Epub 2004 Jan 22. Blood. 2004. PMID: 14739228 Free article.

9

Inhibition of interferon gamma-induced macrophage microbicidal activity against Leishmania major by liposomes: inhibition is dependent upon composition of phospholipid headgroups and fatty acids.

Gilbreath MJ, Fogler WE, Swartz GM Jr, Alving CR, Meltzer MS. Gilbreath MJ, et al. Among authors: swartz gm jr. Int J Immunopharmacol. 1989;11(2):103-10. doi: 10.1016/0192-0561(89)90061-1. Int J Immunopharmacol. 1989. PMID: 2495252

10

Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.

Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Hembrough TA, et al. Among authors: swartz gm. Cancer Res. 2003 Jun 1;63(11):2997-3000. Cancer Res. 2003. PMID: 12782609

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page